Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $24 to $25.
Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $24 to $25.